drugset / Trial / NCT05162118
Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This is a multicenter, open, single-arm design clinical trial coducted in HSV-seropositive subjects with advanced pancreatic cancer to determine the safety, tolerability and preliminary efficacy of VG161 combined with PD-1 inhibitor (Nivolumab Injection).
Timeline
- Start
- 2022-03-08
- Primary completion
- 2025-03-22
- Completion
- 2025-12-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | VG161 | Unknown | 1e+08 unknown | — |
| Subject | VG161 | Unknown | 1.5e+08 unknown | — |